NCT00298467View on ClinicalTrials.gov

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

PHASE2WithdrawnINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2006

Conditions
Lymphoma, Large-Cell
Interventions
DRUG

MDX-060

Trial Locations (8)

14263

Roswell Park Cancer Center, Buffalo

28078

Carolina BioOncology Institute, Huntersville

55905

Mayo Clinic, Rochester

59037

Centre Hospitalier Regional Unv. de Lille, Hopital Claude Huriez, Lille

91010

City of Hope, National Medical Center, Duarte

92093

Moores UCSD Cancer Center, La Jolla

93710

California Oncology of the Central Valley, Fresno

08901

The Cancer Institute of New Jersey - Robert Wood Johnson Unv. Hosp., New Brunswick

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00298467 - MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | Biotech Hunter | Biotech Hunter